A one-year efficacy assessment of subcutaneous immunotherapy in dust mite allergic rhinitis patients based on clinical symptoms and objective biomarkers

Abstract

Objective: To evaluate the 1-year efficacy of subcutaneous immunotherapy (SCIT) in treating dust mite-induced allergic rhinitis (AR) and establish objective biomarkers for efficacy monitoring.

Methods: Fifty-nine AR patients underwent 1-year SCIT. Subjective symptoms were assessed via total nasal symptom score (TNSS), combined symptom/medication score (CSMS), and mini rhinoconjunctivitis quality of life questionnaire (MiniRQLQ). Serum total immunoglobulin E (tIgE), Dermatophagoides species-specific IgE (Der p-sIgE), and component-specific IgE (Der p1/2/10/23) were measured. IgE-facilitated allergen binding (IgE-FAB) assay evaluated blocking antibody activity.

Results The mean TNSS, CSMS, and MiniRQLQ scores were significantly reduced by 28.60% (p < 0.001), 28.60% (p = 0.006), and 24.30% (p < 0.001) respectively after 1 year of SCIT treatment. SCIT treatment significantly elevated serum tIgE and Der p sIgE levels (p < 0.001), with a pronounced increase in component-specific IgE positivity for Der p1 and Der p23 (p < 0.001). The IgE-FAB assay demonstrated that the average suppression of IgE-allergen binding in serum by 1-year SCIT was 4.48% (p < 0.001).

Conclusion SCIT markedly reduces subjective symptoms in patients with dust mite AR over a 1-year treatment period. Component-sIgE levels and IgE-FAB inhibition could function as objective biomarkers for assessing immunotherapy efficacy, thus facilitating tailored clinical interventions.

Keywords

allergen component / allergic rhinitis / blocking antibodies / dust mites / subcutaneous immunotherapy

References

[1] Bousquet J , Anto JM , Bachert C , et al. Allergic rhinitis. Nat Rev Dis Primers. 2020; 6 (1): 95.

[2] Brożek JL , Bousquet J , Agache I , et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017; 140 (4): 950- 958.

[3] Law M , Morris JK , Wald N , Luczynska C , Burney P . Changes in atopy over a quarter of a century, based on cross sectional data at three time periods. BMJ. 2005; 330 (7501): 1187- 1188.

[4] Bachert C , Van Cauwenberge P , Olbrecht J , Van Schoor J . Prevalence, classification and perception of allergic and nonallergic rhinitis in Belgium. Allergy. 2006; 61 (6): 693- 698.

[5] Linneberg A . Changes in atopy over 25 years:allergy epidemic has spread to old age. BMJ. 2005; 331 (7512): 352.

[6] Li X , Xu X , Li J , et al. Direct and indirect costs of allergic and nonallergic rhinitis to adults in Beijing, China. Clin Transl Allergy. 2022; 12 (4): e12148.

[7] Cheng L , Chen J , Fu Q , et al. Chinese society of allergy guidelines for diagnosis and treatment of allergic rhinitis. Allergy Asthma Immunol Res. 2018; 10 (4): 300- 353.

[8] Guan K , Liu B , Wang M , et al. Principles of allergen immunotherapy and its clinical application in China: contrasts and comparisons with the USA. Clin Rev Allergy Immunol. 2019; 57 (1): 128- 143.

[9] Arlian LG , Platts-Mills TAE . The biology of dust mites and the remediation of mite allergens in allergic disease. J Allergy Clin Immunol. 2001; 107 (3): S406- S413.

[10] Zheng YW , Lai XX , Zhao DY , et al. Indoor allergen levels and household distributions in nine cities across China. Biomed Environ Sci. 2015; 28 (10): 709- 717.

[11] Guan K , Zhu W , Sha L , et al. Prevalence of sensitization to aeroallergens in greater Beijing region children with respiratory allergy. Front Pediatr. 2022; 10: 848357.

[12] Li J , Sun B , Huang Y , et al. A multicentre study assessing the prevalence of sensitizations in patients with asthma and/or rhinitis in China. Allergy. 2009; 64 (7): 1083- 1092.

[13] Huang HJ , Resch-Marat Y , Rodriguez-Dominguez A , et al. Underestimation of house dust mite-specific IgE with extract-based ImmunoCAPs compared with molecular ImmunoCAPs. J Allergy Clin Immunol. 2018; 142 (5): 1656- 1659.e9.

[14] Lam HY , Tergaonkar V , Ahn KS . Mechanisms of allergen-specific immunotherapy for allergic rhinitis and food allergies. Biosci Rep. 2020; 40 (4): BSR20200256.

[15] Berings M , Karaaslan C , Altunbulakli C , et al. Advances and highlights in allergen immunotherapy:on the way to sustained clinical and immunologic tolerance. J Allergy Clin Immunol. 2017; 140 (5): 1250- 1267.

[16] Rodríguez-Domínguez A , Berings M , Rohrbach A , et al. Molecular profiling of allergen-specific antibody responses may enhance success of specific immunotherapy. J Allergy Clin Immunol. 2020; 146 (5): 1097- 1108.

[17] Bao Y , Chen J , Cheng L , et al. Chinese Guideline on allergen immunotherapy for allergic rhinitis. J Thorac Dis. 2017; 9 (11): 4607- 4650.

[18] Roberts G , Pfaar O , Akdis CA , et al. EAACI guidelines on allergen immunotherapy:allergic rhinoconjunctivitis. Allergy. 2018; 73 (4): 765- 798.

[19] Zhang L , Wang C , Han D , Wang X , Zhao Y , Liu J . Comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus in the treatment of persistent allergic rhinitis. Int Arch Allergy Immunol. 2009; 148 (2): 161- 169.

[20] Jiang Z , Xiao H , Zhang H , Liu S , Meng J . Comparison of adverse events between cluster and conventional immunotherapy for allergic rhinitis patients with or without asthma: a systematic review and meta-analysis. Am J Otolaryngol. 2019; 40 (6): 102269.

[21] Ren L , Wang C , Xi L , Gao Y , Zhang Y , Zhang L . Long-term efficacy of HDM-SCIT in pediatric and adult patients with allergic rhinitis. Allergy Asthma Clin Immunol. 2023; 19 (1): 20.

[22] Juniper T , Ferrie R , Ferrie , Roberts. . Development and validation of the mini rhinoconjunctivitis quality of life questionnaire. Clin Exp Allergy. 2000; 30 (1): 132- 140.

[23] Shamji MH , Wilcock LK , Wachholz PA , et al. The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods. 2006; 317 (1-2): 71- 79.

[24] Xiang L , Zhao J , Bao Y , et al. Expert consensus on mite-specific immunotherapy for pediatric allergic airway diseases. Chinese Journal of Practical Pediatrics. 2018; 33 (16): 1215- 1223.

[25] Kim JY , Jang Mjin , Kim DY , Park SW , Han DH . Efficacy of subcutaneous and sublingual immunotherapy for house dust mite allergy: a network meta-analysis-based comparison. J Allergy Clin Immunol Pract. 2021; 9 (12): 4450- 4458.e6.

[26] Schubert R , Eickmeier O , Garn H , et al. Safety and immunogenicity of a cluster specific immunotherapy in children with bronchial asthma and mite allergy. Int Arch Allergy Immunol. 2009; 148 (3): 251- 260.

[27] Tabar AI , Echechipía S , García BE , et al. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J Allergy Clin Immunol. 2005; 116 (1): 109- 118.

[28] Fan Q , Liu X , Gao J , Huang S , Ni L . Comparative analysis of cluster versus conventional immunotherapy in patients with allergic rhinitis. Exp Ther Med. 2017; 13 (2): 717- 722.

[29] Pfaar O , Klimek L , Fischer I , et al. Safety of two cluster schedules for subcutaneous immunotherapy in allergic rhinitis or asthma patients sensitized to inhalant allergens. Int Arch Allergy Immunol. 2009; 150 (1): 102- 108.

[30] Canonica GW , Baena-Cagnani CE , Bousquet J , et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy. 2007; 62 (3): 317- 324.

[31] Sharma M , Khaitan T , Raman S , Jain R , Kabiraj A . Determination of serum IgE and eosinophils as a diagnostic indicator in allergic rhinitis. Indian J Otolaryngol Head Neck Surg. 2019; 71 (S3): 1957- 1961.

[32] Baba SM , Rasool R , Gull A , et al. Effectiveness of sublingual immunotherapy in the treatment of HDM-induced nasobronchial allergies: a 3-year randomized case-control study from kashmir. Front Immunol. 2021; 12: 723814.

[33] Jiang Z , Meng J . Changes in biological indicators and their significance during allergen-specific immunotherapy. Chinese Journal of Clinical Immunology and Allergic Reactions. 2021; 15 (5): 586- 587.

[34] Vrtala S , Sperr WR , Reimitzer I , et al. cDNA cloning of a major allergen from timothy grass (Phleum pratense) pollen;characterization of the recombinant Phl pV allergen. J Immunol. 1993; 151 (9): 4773- 4781.

[35] Weghofer M , Grote M , Resch Y , et al. Identification of der p23, a peritrophin-like protein, as a new major Dermatophagoides pteronyssinus allergen associated with the peritrophic matrix of mite fecal pellets. J Immunol. 2013; 190 (7): 3059- 3067.

[36] Muddaluru V , Valenta R , Vrtala S , et al. Comparison of house dust mite sensitization profiles in allergic adults from Canada, Europe, South Africa and USA. Allergy. 2021; 76 (7): 2177- 2188.

[37] Sjoerdsma J , Mejia F , Bilgicer B . Determination of immunogenic epitopes in major house dust mite allergen, Der p2, via nanoallergens. Ann Allergy Asthma Immunol. 2022; 129 (2): 231- 240.e2.

[38] Weghofer M , Thomas WR , Kronqvist M , et al. Variability of IgE reactivity profiles among European mite allergic patients. Eur J Clin Invest. 2008; 38 (12): 959- 965.

[39] Weghofer M , Grote M , Resch Y , et al. Identification of der p 23, a peritrophin-like protein, as a new major Dermatophagoides pteronyssinus allergen associated with the peritrophic matrix of mite fecal pellets. J Immunol. 2013; 190 (7): 3059- 3067.

[40] Chen KW , Zieglmayer P , Zieglmayer R , et al. Selection of house dust mite-allergic patients by molecular diagnosis may enhance success of specific immunotherapy. J Allergy Clin Immunol. 2019; 143 (3): 1248- 1252.

[41] Lai X , Li J , Xiao X , et al. Specific IgG4 production during house dust mite immunotherapy among age, gender and allergic disease populations. Int Arch Allergy Immunol. 2013; 160 (1): 37- 46.

[42] Shamji MH , Kappen JH , Akdis M , et al. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper. Allergy. 2017; 72 (8): 1156- 1173.

[43] Shamji MH , Kappen J , Abubakar-Waziri H , et al. Nasal allergenneutralizing IgG4 antibodies block IgE-mediated responses: novel biomarker of subcutaneous grass pollen immunotherapy. J Allergy Clin Immunol. 2019; 143 (3): 1067- 1076.

[44] Posa D , Perna S , Resch Y , et al. Evolution and predictive value of IgE responses toward a comprehensive panel of house dust mite allergens during the first 2 decades of life. J Allergy Clin Immunol. 2017; 139 (2): 541- 549.

[45] Shamji MH , Wilcock LK , Wachholz PA , et al. The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods. 2006; 317 (1-2): 71- 79.

RIGHTS & PERMISSIONS

The Author(s). Eye & ENT Research published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.